SCHEMBL26967948

SCHEMBL26967948

COC(=O)c1c2n(cc(C3=CCOCC3)c1=O)CCOC2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
SCN9A Q15858 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
GCK P35557 1/20 0.32
CNR2 P34972 1/20 0.31
WDR5 P61964 1/20 0.31
PIK3C3 Q8NEB9 1/20 0.31
ALDH1A1 P00352 3/20 0.31
HPGD P15428 1/20 0.30
ALOX15 P16050 1/20 0.30
MGLL Q99685 1/20 0.30
HSD17B10 Q99714 1/20 0.30
CSF1R P07333 1/20 0.30
LMNA P02545 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM5 P08912 1/20 0.30
THRB P10828 1/20 0.30
CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218069 0.87 CNR2 (0.33) SMN1; SMN2CNR2ALDH1A1HPGDALOX15
SCHEMBL26967898 0.86 SCN9A (0.32) PDE3BPDE3ASCN9APIK3C3
SCHEMBL26967921 0.86 CNR2 (0.35) SMN1; SMN2CNR2ALDH1A1HSD17B10CSF1R
SCHEMBL25529232 0.77 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1HPGDALOX15MGLL
SCHEMBL25529243 0.76 ALDH1A1 (0.39) ALDH1A1HPGDALOX15HSD17B10LMNA
SCHEMBL26967947 0.73 HDAC3 (0.32)
SCHEMBL27218044 0.72 PSMB5 (0.32) CSF1R
SCHEMBL25529231 0.69 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1HPGDALOX15MGLL
SCHEMBL29868495 0.68 PIK3C3 (0.36) PDE3BPDE3ASCN9APIK3C3
SCHEMBL27218064 0.67 PIK3C3 (0.37) PDE3BPDE3ASCN9APIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294804-B1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2026-04-08 EP disclosed
US-20240158393-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. 2024-05-16 US disclosed
EP-4294804-A1 PYRIDONE COMPOUNDS AND METHODS OF USE Exelixis, Inc. (US) 2023-12-27 EP disclosed
WO-2022178205-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. (US) 2022-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158393-A1 PYRIDONE COMPOUNDS AND METHODS OF USE PDXK, PLK2, MAP4K2 PDE3B 909/4885PDE3A 800/4885SCN9A 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.